2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1762 Single-cell and bulk transcriptomic integration reveals immune molecular subtypes associated with prognosis in follicular lymphoma

Hengqi Liu, PhD, Zhong Zheng, PhD2, Ning Zhang3, Cong Sun4, Xianhuo Wang, PhD5, Weili Zhao, PhD6, Huilai Zhang, PhD7
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
4 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
6 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China
7 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Background: Follicular lymphoma (FL) is clinically and biologically heterogeneous. In addition to intrinsic malignant B-cell programs, diverse cell types and functional states within the tumor microenvironment (TME) may influence clinical outcomes. However, resolving these states across large patient cohorts and defining their clinical relevance remain challenging. Here, we integrated single-cell RNA-sequencing (scRNA-seq) data with bulk tumor transcriptomes to define FL cell states and multicellular ecotypes comprising malignant B-cell and microenvironmental states.

Methods: Five FL scRNA-seq datasets and 18 bulk transcriptomic cohorts were included. EcoTyper identified cell states in a scRNA-seq discovery cohort; these were recovered in three independent scRNA-seq cohorts and quantified in bulk tumors. Malignant B-cell states were characterized through functional, genomic, and clonotype analyses. Nonnegative matrix factorization of state-abundance profiles from 865 cases derived four follicular lymphoma ecotypes (FLE1-FLE4). Relationships with progression-free survival (PFS), progression of disease within 24 months (POD24), and FLIPI/FLIPI2 were assessed. Treatment outcomes were explored retrospectively in 310 patients receiving rituximab-lenalidomide (R2; n=112) or anti-CD20 antibody-based immunochemotherapy (n=198).

Results: Harmonized annotation identified nine major cell populations across scRNA-seq cohorts. The discovery cohort yielded 30 stable states, which were recovered in three independent scRNA-seq cohorts and multiple bulk cohorts. Malignant B cells comprised four states (S1-S4), and dominant B-cell clonotypes spanned multiple states, consistent with transcriptional plasticity within a shared clonal background. S2 exhibited a dark-zone germinal center-like program with attenuated MHC class II and antigen-presentation programs. In patients receiving immunochemotherapy, S2 remained associated with shorter PFS after adjustment for FLIPI (HR, 1.77; 95% CI, 1.12-2.81; P=.015) or FLIPI2 (HR, 1.74; 95% CI, 1.07-2.82; P=.025). Microenvironmental states showed distinct, treatment-dependent relationships with PFS, underscoring their clinical relevance beyond overall lineage abundance. Subsequently, analysis of recurrent co-occurrence patterns in state-abundance profiles recovered from bulk cohorts defined four follicular lymphoma ecotypes (FLE1-FLE4), each comprising distinct combinations of malignant B-cell and microenvironmental states. FLE1 exhibited an immune-desert phenotype characterized by S2 predominance, enrichment of CREBBP mutations, and attenuation of MHC class II and antigen-presentation programs. By contrast, FLE4 showed extensive immune infiltration with enrichment of immune checkpoint, regulatory T-cell, and myeloid-suppressive programs. Among patients treated with immunochemotherapy, PFS varied significantly across ecotypes (P=.027), as did POD24 rates (P=.015); FLE1 had the shortest PFS and highest POD24 rate. In an independent immunochemotherapy-treated cohort, FLE1 remained associated with shorter PFS after adjustment for FLIPI (HR, 2.45; 95% CI, 1.45-4.15; P<.001) or FLIPI2 (HR, 2.70; 95% CI, 1.58-4.60; P<.001). Finally, treatment-outcome relationships across ecotypes were examined in a real-world cohort. Overall, R2 was not associated with longer PFS than immunochemotherapy (P=.15). Within FLE1, however, R2 was associated with longer PFS (log-rank P=.031), and this association remained significant after adjustment for FLIPI (HR, 0.40; 95% CI, 0.17-0.94; P=.035). The estimate remained directionally consistent after FLIPI2 adjustment but did not reach statistical significance (HR, 0.45; 95% CI, 0.19-1.07; P=.070). No treatment-related PFS associations were observed in FLE2-FLE4.

Conclusions: Our findings define a cell-state atlas of FL and four multicellular ecotypes linking malignant B-cell and microenvironmental programs. FLE1 represents a high-risk, immune-desert ecotype with impaired antigen-presentation programs and adverse outcomes following immunochemotherapy, whereas FLE4 is immune-rich but immunosuppressive. The more favorable PFS observed with R2 than with immunochemotherapy in FLE1 suggests that R2 may partially mitigate the adverse prognosis of this ecotype. However, this potential benefit warrants further investigation in prospective trials.

Hengqi Liu, PhD: No relevant conflicts of interest to declare.